Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chuikyo's Pilot For Premium Reimbursement Pricing Under Review: One Of Three Fates By Year-end

This article was originally published in PharmAsia News

You may also be interested in...



Japan Pharma Gearing Up For Battle In Reimbursement Talks As Tax Landscape Shifts

Increased consumption tax and tax credits for R&D offer a new playing field as 2014 price revision talks take shape.

Japan Pharma Gearing Up For Battle In Reimbursement Talks As Tax Landscape Shifts

Increased consumption tax and tax credits for R&D offer a new playing field as 2014 price revision talks take shape.

Japan's Biennial Price Cuts Spare Innovation But Punish Overachievers

Eisai took the biggest hit in the latest price revisions due to its lead products exceeding peak sales in Japan, according to analysts.

Related Content

UsernamePublicRestriction

Register

SC076536

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel